Lilly’s Foundayo wins EMA panel backing for obesity and type 2 diabetes
RegulatorypositiveFoundayoWegovy (oral)Positive
AI Analysis
Summary
Eli Lilly's oral GLP-1 receptor agonist Foundayo received backing from an EMA panel for obesity and type 2 diabetes. It is on course to join Novo Nordisk's oral Wegovy in the European oral GLP-1RA market.
Outcome Details
EMA panel (CHMP) backing for Foundayo in obesity and type 2 diabetes, putting it on course to join Novo's oral Wegovy in the European oral GLP-1RA market.
Importance:8/10
Sentiment:
0.70
EMACHMPoral GLP-1obesitytype 2 diabetespositive opinionEurope
Related Companies
Read the original article
Published by Pharmaceutical Technology on October 16, 2026 2:29 PM